Stereotaxis announces first atrial fibrillation procedures performed with performed with magnetic irrigated catheter

Stereotaxis, Inc. has announced that the first atrial fibrillation procedures performed with its partnered magnetic irrigated catheter were successfully completed over the course of the past week.

The magnetic irrigated catheter has CE Mark approval for the remote ablation of arrhythmias and is being released in phases to physicians in Europe. Details from completed cases will be provided at the Company's earnings call, which is scheduled for Thursday, November 8, 2007, at 8:30 a.m. Eastern Time.

"The first uses of our partnered irrigated catheter in Europe are a double achievement," said Bevil Hogg, CEO of Stereotaxis. "First, the cases were remarkable for their efficiency and efficacy, and we are extremely pleased with the results. Secondly, combined with our Stereotaxis Magnetic Navigation System and new NaviLine(TM) software, the irrigated catheter completes Stereotaxis' total solution for atrial fibrillation, a solution that we believe will significantly advance the treatment of complex arrhythmias and potentially become standard of care for a growing number of cases. Near term, we believe that widespread adoption of our partnered magnetic irrigated catheter in Europe will bring even greater simplicity and safety to atrial fibrillation procedures performed there, and we look forward to these clinical benefits becoming available to patients and clinicians in the U.S. after appropriate regulatory approval."